ARDX ARDELYX, INC.

Nasdaq Pharmaceutical Preparations DE CIK: 0001437402
AI RATING
SELL
82% Confidence

Investment Thesis

Ardelyx exhibits strong revenue growth (+22.1% YoY) demonstrating market traction, but operates with severe fundamental deterioration: the company is burning $32M+ annually in operating cash flow with only $31M in cash on hand (~1-year runway), carries $203.5M long-term debt that cannot be serviced from negative operating income, and maintains critically low gross margins (5%) raising sustainability concerns. Near-term refinancing risk and path to profitability remain unclear.

Strengths

  • + Strong revenue growth of 22.1% YoY indicating market demand and product adoption
  • + Healthy current ratio of 3.49x and quick ratio of 2.32x providing short-term liquidity cushion
  • + Positive gross profit generation ($4.7M) despite low margins, demonstrating core product viability

Risks

  • ! Severe cash burn: -$32.2M operating cash flow with only $31.2M cash on hand (~1-year runway at current rate)
  • ! High debt burden ($203.5M long-term) with negative interest coverage ratio (-13.9x), indicating inability to service debt from operations
  • ! Critically low gross margin (5%) and operating margin (-34.7%) raise questions about cost structure and pricing power sustainability
  • ! Company dependent on future financing, partnerships, or profitability turnaround with no clear catalyst or timeline

Key Metrics to Watch

Financial Metrics

Revenue
94.5M
Net Income
-37.6M
EPS (Diluted)
$-0.15
Free Cash Flow
-32.3M
Total Assets
504.5M
Cash
31.2M

Profitability Ratios

Gross Margin 5.0%
Operating Margin -34.7%
Net Margin -39.8%
ROE -25.3%
ROA -7.5%
FCF Margin -34.2%

Balance Sheet & Liquidity

Current Ratio
3.49x
Quick Ratio
2.32x
Debt/Equity
1.37x
Debt/Assets
70.5%
Interest Coverage
-13.92x
Long-term Debt
203.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-06T16:56:00.168100 | Data as of: 2026-03-31 | Powered by Claude AI